AX-024

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

AX-024

CAS No. : 1370544-73-2

MCE 国际站：AX-024

产品活性：AX-024 是一种口服可利用的，首创的 TCR-Nck 相互作用抑制剂，可选择性地抑制 TCR 触发的 T 细胞活化，IC₅₀ 值为 1 nM。AX-024 通过靶向 SH3 结构域调节细胞信号传导。AX-024 具有低毒、高效、高选择性的特点。AX-024 有效抑制白细胞介素-6 (IL-6)，肿瘤坏死因子-α (TNFα)，干扰素-γ (IFN-γ)，IL-10 和 IL-17A 的产生。

研究领域：Apoptosis  |  Immunology/Inflammation

作用靶点：TNF Receptor  |  Interleukin Related  |  IFNAR

In Vitro: AX-024 is >10,000-fold more potent than the AX-000 hit in terms of inhibition of TCR-triggered T cell proliferation. The IC₅₀ of AX-024 in this assay is 1 nM, although it shows inhibitory effects at a concentration of 1 pM or less. AX-024 is also a much more potent inhibitor of cytokine release by human peripheral blood mononuclear cells stimulated with anti-CD3 than AX-000, strongly hindering interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IL-10, and IL-17A production at a concentration of 10 nM. In CD8⁺ T cells of OT1 TCR transgenic (OT1^Tg) mice bearing wild-type (WT) AX-024 strongly inhibits T cell proliferation at a concentration of 0.1 nM when OT1^Tg T cells are WT for the PRS mutation. Coimmunoprecipitation experiments in these cells show that Nck recruitment to the TCR is induced upon stimulation in the absence of drug but is inhibited in the presence of AX-024 in a dose-dependent manner at concentrations starting from 1 nM.

In Vivo: AX-024-treated group presents less scales and reduces skin thickening compare to the vehicle group. AX-024 significantly reduces thickening of both skin layers, but more effectively of the dermis, which rather resembles that of mice treated with a control cream lacking imiquimod (IMQ). AX-024 significantly diminishes the number of airway inflammatory cells in both assays. Mice receiving AX-024 rapidly recovers from neurological impairment and weight loss, becoming symptom-free by day 30, unlike mice that receives the vehicle, in which ataxia and loss of the righting reflex persist.

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  Differentiation Inducing Compound Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  Angiogenesis-Related Compound Library  |  Rare Diseases Drug Library  |  Antidepressant Compound Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Heterocyclic Compound Library  |  Pain-Related Compound Library  |  Mitochondrial Protection Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Autoimmune Disease Compound Library  |  Highly Selective Inhibitors Library  |  Cytokine Inhibitors Library  |  Resatorvid  |  CCCP  |  Disulfiram  |  Polyinosinic-polycytidylic acid  |  Vadimezan  |  Deucravacitinib  |  2',3'-cGAMP sodium  |  Shikonin  |  Raleukin  |  Infliximab  |  Fisetin  |  Apilimod  |  Tocilizumab  |  Oxidopamine hydrobromide  |  Dupilumab  |  Adalimumab  |  Etanercept  |  N-Formyl-Met-Leu-Phe  |  QNZ  |  Theophylline  |  LMT-28  |  R-7050  |  Apremilast  |  Secukinumab  |  IFN alpha-IFNAR-IN-1 hydrochloride  |  RO8191  |  Clofazimine  |  C25-140

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds